Other languages Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Real-time Estimate Cboe BZX Other stock markets 10:44:11 2024-04-25 am EDT			5-day change	1st Jan Change
8.285 ^USD	-5.31%		-10.32%	+162.38%

Apr. 10	Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	CI
Mar. 18	Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arcutis Promotes Todd Tucker to Chief Human Resources Officer	Mar. 11
Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting	Mar. 10
Arcutis Biotherapeutics Raises $172.5 Million in Common Stock Offering	Mar. 04
Arcutis Plans $150 Million Offering, Signs Collaboration, Licensing Deal for Roflumilast in Japan; Shares Fall After Hours	Feb. 28
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Arcutis Biotherapeutics, Inc. Announces Publication of Positive Results from the Pivotal Phase 3 Trial Evaluating ZORYVE (roflumilast) Foam	Jan. 29
Arcutis Biotherapeutics Launches ZORYVE Topical Foam to Treat Seborrheic Dermatitis	Jan. 22
Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids	Jan. 14
Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii	Jan. 14
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Dec. 18
Sector Update: Health Care	Dec. 18
Top Premarket Gainers	Dec. 18
Arcutis Biotherapeutics Gets FDA Approval for Seborrheic Dermatitis Treatment -- Shares Surge Premarket	Dec. 18
MORNING BRIEFING - USA/Asien	Dec. 18
US FDA approves Arcutis' drug to treat chronic skin disease	Dec. 15
FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older	Dec. 15
Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6	Nov. 29
Arcutis Biotherapeutics, Inc. Announces Executive Changes	Nov. 03
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Other languages

Filters